Athersys, Inc.  

(Public, NASDAQ:ATHX)   Watch this stock  
Find more results for Harrington Campbell
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 0.90 - 3.43
Open     -
Vol / Avg. 0.00/2.73M
Mkt cap 111.06M
P/E     -
Div/yield     -
EPS -0.29
Shares 82.88M
Beta 0.60
Inst. own 27%
Aug 10, 2015
Q2 2015 Athersys Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Jun 24, 2015
Athersys Inc Annual Shareholders Meeting - 8:00AM EDT - Add to calendar
May 11, 2015
Q1 2015 Athersys Inc Earnings Call
May 11, 2015
Q1 2015 Athersys Inc Earnings Release
Apr 29, 2015
Athersys Inc Corporate Call to Present Interim Results of MultiStem Phase 2 Study - Webcast
Mar 24, 2015
Athersys Inc at Biotechnology Industry Organization (BIO) Asia International Conference
Mar 12, 2015
Q4 2014 Athersys Inc Earnings Call - Webcast
Mar 12, 2015
Q4 2014 Athersys Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -1707.52% -1360.57%
Operating margin -942.95% -1787.55%
EBITD margin - -1765.37%
Return on average assets -145.31% -70.21%
Return on average equity -250.89% -108.47%
Employees 57 -
CDP Score - -


3201 Carnegie Ave
CLEVELAND, OH 44115-2634
United States - Map
+1-216-4319900 (Phone)
+1-216-3619495 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Athersys Inc. is a biopharmaceutical company engaged in the field of regenerative medicine. The Company is engaged in research and product development activities. The Company is evaluating its lead platform product, MultiStem, in Phase II clinical trials and an investigator-led Phase I trial. The Company clinical development program includes Inflammatory Bowel Disease, Ischemic Stroke, Acute Myocardial Infarction and Hematopoietic Stem Cell Transplant/GvHD. The Company is conducting double blind, placebo controlled trial with the partner Pfizer, in ulcerative colitis patients. The Company is conducting double blind, placebo-controlled trial for the treatment of Ischemic Stroke. The Company is engaged in preclinical development and evaluation of MultiStem therapy in inflammatory and immune, neurological and cardiovascular diseases. The Company is also engaged in the development of small molecule therapies to treat obesity and schizophrenia.

Officers and directors

Gil Van Bokkelen Ph.D. Chairman of the Board, Chief Executive Officer
Age: 54
Bio & Compensation  - Reuters
William Lehmann Jr., J.D. President, Chief Operating Officer
Age: 49
Bio & Compensation  - Reuters
John J. Harrington Ph.D. Executive Vice President, Chief Scientific Officer, Director
Age: 47
Bio & Compensation  - Reuters
Robert J. Deans Ph.D. Executive Vice President - Regenerative Medicine
Age: 63
Bio & Compensation  - Reuters
Laura K. Campbell CPA Vice President - Finance
Age: 51
Bio & Compensation  - Reuters
Lee E. Babiss Ph.D. Lead Independent Director
Age: 59
Bio & Compensation  - Reuters
Ismail Kola Ph.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
Lorin Jeffry Randall Independent Director
Age: 71
Bio & Compensation  - Reuters
Kenneth H. Traub Independent Director
Age: 53
Bio & Compensation  - Reuters
Jack L. Wyszomierski Independent Director
Age: 59
Bio & Compensation  - Reuters